Multicorp International Inc (MCIC) 0.0011 $MCIC
Post# of 273254
Posted On: 09/23/2016 1:20:58 AM
Multicorp International Inc (MCIC) 0.0011 $MCIC
MultiCorp International, Inc. to Develop 4 Arm Study for Emergency Room Clinical Trials With Patented Migraine Medicine
Marketwired - Thu Jan 21, 8:00AM CST
MultiCorp International, Inc. (OTC PINK: MCIC) has received a report from the U.S. Food and Drug Administration that gives the company specific guidelines in creating a 4 arm study to administer the patented migraine medicine in an emergency room setting.
Compass Point Research to Collaborate With NDA Partners to Develop Migraine Combination Drug
Marketwired - Tue Apr 07, 4:00PM CDT
Lori Nesbitt, PharmD, Chief Executive Officer of Compass Point Research, announced today that the company has entered into an agreement with NDA Partners LLC, a highly regarded medical product development and regulatory strategy consultancy, to collaborate in the development of a new combination drug for the treatment of migraine headaches. Compass Point has been retained by the drug sponsor, MultiCorp International, Inc., a publicly traded company located in Sun Valley, CA, to manage the product development program, and NDA Partners will provide the drug development and regulatory expertise needed to prepare a development plan for a 505(b)(2) NDA submission to the US Food & Drug Administration (FDA) and to manage a preIND meeting with the FDA review division.
MultiCorp International, Inc. Engages Compass Point Research to Collaborate With NDA Partners to Develop Patented Migraine Combination Drug
Marketwired - Tue Mar 31, 8:02AM CDT
MultiCorp International, Inc, (OTC PINK: MCIC) has engaged Compass Point Research of Nashville, Tennessee to manage the product development program, and NDA Partners, of Rochelle, Virginia will provide the drug development and regulatory expertise needed to prepare a development plan for a 505(b)(2) NDA submission to the US Food & Drug Administration (FDA) and to manage a pre IND meeting with the FDA review division.
MultiCorp International, Inc. to Develop 4 Arm Study for Emergency Room Clinical Trials With Patented Migraine Medicine
Marketwired - Thu Jan 21, 8:00AM CST
MultiCorp International, Inc. (OTC PINK: MCIC) has received a report from the U.S. Food and Drug Administration that gives the company specific guidelines in creating a 4 arm study to administer the patented migraine medicine in an emergency room setting.
Compass Point Research to Collaborate With NDA Partners to Develop Migraine Combination Drug
Marketwired - Tue Apr 07, 4:00PM CDT
Lori Nesbitt, PharmD, Chief Executive Officer of Compass Point Research, announced today that the company has entered into an agreement with NDA Partners LLC, a highly regarded medical product development and regulatory strategy consultancy, to collaborate in the development of a new combination drug for the treatment of migraine headaches. Compass Point has been retained by the drug sponsor, MultiCorp International, Inc., a publicly traded company located in Sun Valley, CA, to manage the product development program, and NDA Partners will provide the drug development and regulatory expertise needed to prepare a development plan for a 505(b)(2) NDA submission to the US Food & Drug Administration (FDA) and to manage a preIND meeting with the FDA review division.
MultiCorp International, Inc. Engages Compass Point Research to Collaborate With NDA Partners to Develop Patented Migraine Combination Drug
Marketwired - Tue Mar 31, 8:02AM CDT
MultiCorp International, Inc, (OTC PINK: MCIC) has engaged Compass Point Research of Nashville, Tennessee to manage the product development program, and NDA Partners, of Rochelle, Virginia will provide the drug development and regulatory expertise needed to prepare a development plan for a 505(b)(2) NDA submission to the US Food & Drug Administration (FDA) and to manage a pre IND meeting with the FDA review division.
(0)
(0)Scroll down for more posts ▼